Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. mFLUSIVA is most often covered alongside FDA, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention mFLUSIVA, all published on August 6, 2026.
Last mentioned: Aug 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. mFLUSIVA is most often covered alongside FDA, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention mFLUSIVA, all published on August 6, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering mFLUSIVA. Shared-story counts are live from our verified record — not editorial picks.
The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Source: kawc.org · wknofm.org
mFLUSIVA is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
